e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Advances in the future treatment of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans
Naimish Patel (Waltham, United States of America), Naimish Patel, Danen Cunoosamy, Tove Hegelund-Myrback, Rikard Pehrson, Ziad Taib, Paul Jansson, Sofia Lundin, Steven Greenaway, Graham Clarke, Leonard Siew
Source:
International Congress 2015 – Advances in the future treatment of COPD
Session:
Advances in the future treatment of COPD
Session type:
Oral Presentation
Number:
483
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Naimish Patel (Waltham, United States of America), Naimish Patel, Danen Cunoosamy, Tove Hegelund-Myrback, Rikard Pehrson, Ziad Taib, Paul Jansson, Sofia Lundin, Steven Greenaway, Graham Clarke, Leonard Siew. AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans. Eur Respir J 2015; 46: Suppl. 59, 483
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Cryptotanshinone attenuates airway Inflammation induced by cigarette smoke in mice
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation
Source: International Congress 2014 – Animal models: asthma, COPD and beyond
Year: 2014
Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD
Source: Annual Congress 2005 - Protease-antiprotease revisited
Year: 2005
Ceramide-1-phosphate attenuates cigarette smoke induce lung inflammation
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease
Source: International Congress 2015 – Advances in asthma and allergy in animal models
Year: 2015
Rapamycin protects OVA induced asthma in mice through regulating autophagy
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Quercetin attenuates inflammation in cigarette smoke stimulated airway epithelial cells: Possible involvement of autophagy
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
LATE-BREAKING ABSTRACT: Effect of inhaled kinase inhibitor on airway inflammation assessed in induced sputum after challenge with inhaled lipopolysaccharide
Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept